Protox Completes Prostate Cancer Trial Recruitment



    VANCOUVER, June 6 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today
announced that it has completed recruitment of patients for its Phase I study
of PRX302 to treat localized, recurrent prostate cancer. The Company is on
track to report top line data from this study by mid year.
    "This is a significant milestone for Protox as we march towards our goal
of providing a safe and effective treatment for millions of men suffering with
localized prostate cancer," said Dr. Fahar Merchant, President and CEO of
Protox Therapeutics. "We are looking forward to delivering top line data from
this trial shortly and expect to initiate a Phase II clinical trial before the
end of the year."
    PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent
once it is activated by prostate specific antigen (PSA), which is produced in
high levels by prostate cancer and hyperplastic prostate cells. Once
activated, PRX302 selectively destroys the cells by punching holes in the cell
membrane.

    About Prostate Cancer

    Prostate cancer is a leading cause of cancer death in North American men.
One in every six men is diagnosed with prostate cancer during his lifetime. It
is estimated that during 2007 approximately 250,000 new cases of prostate
cancer will be diagnosed and over 30,000 men will die from the disease in
North America. Current treatment options for localized prostate cancer include
surgery and radiation therapy. Serious side effects are associated with these
therapies including erectile dysfunction, incontinence, urinary dysfunction
and bowel problems.

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. The company is actively developing two distinct but complementary
platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs
in development. A Phase IIa clinical trial into the use of PRX321 (INxin) for
the treatment of primary brain cancer has been completed and the drug has
received Fast Track Designation and Orphan Drug Status from the US FDA. In
addition, a Phase I trial has been completed for PRX321 to treat patients with
renal cell carcinoma and non-small cell lung cancer. Patient enrollment has
been completed for a Phase I clinical trial into the use of PRX302 (PORxin)
for the treatment of localized prostate cancer. A Phase I clinical study of
PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate)
is ongoing.

    NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
    RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
    ADEQUACY OR ACCURACY OF THIS RELEASE.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 484-0975, jbeesley@protoxtherapeutics.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x241,
mmoore@equicomgroup.com

Organization Profile

Sophiris Bio, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890